

"the Notice"). The specific amendment to the specification is further discussed below in detail.

None of the above amendments adds any new matter.

## THE AMENDMENT

In the Specification

In response to the Notice, Applicants submit specification page 34 which recites the Sequence Listing pursuant to 37 C.F.R. §§ 1.77(b) and 1.821-1.825.

## CONCLUSION

Applicants request that the Examiner consider the foregoing remarks and enter the indicated amendment prior to substantive examination of this application.

Respectfully submitted,

Andrea L. C. Robidoux (Reg. No. 47,902)  
Agent for Applicants  
c/o Vertex Pharmaceuticals Inc.  
130 Waverly St.  
Cambridge, MA 02139-4242  
Tel: (617)444-6731